Dolutegravir + Rilpivirine
Form: Tablet
Strength: 50 mg / 25 mg
Reference Brands: Juluca(EU & US)
Category: Anti Viral
Dolutegravir + Rilpivirine, marketed as Juluca, is a once-daily, two-drug regimen for the maintenance treatment of HIV-1 infection. It combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to effectively suppress HIV replication. Approved by the US FDA and EMA, Juluca is intended for adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure. Juluca offers a simplified treatment option with fewer drugs, reduced side effects, and excellent tolerability, making it ideal for long-term HIV management.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Zanamivir
Strength: 5 mg/blister
Form: Inhalation powder
Reference Brands: Relenza(EU & US)
View Details Get Enquiry
Oseltamivir Phosphate Capsule
Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)
Form: Capsules and Oral solution
Reference Brands: Tamiflu(EU & US)
View Details Get Enquiry
Amantadine
Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg
Form: Tablet; Capsule; Oral Solution and ER Capsule
Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)
View Details Get Enquiry
Glecaprevir + Pibrentasvir
Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg
Form: Tablet
Reference Brands: Mavyret (US); Maviret (EU)
View Details Get Enquiry